W. Robert Bishop

8.8k citations

71 papers · 5.9k indexed · 2 hit papers · h-index 35

Impact in

Oncology top 1%
- Cancer-related Molecular Pathways
Molecular Biology top 1%
- Protein Kinase Regulation and GTPase Signaling
- Cell death mechanisms and regulation
- PI3K/AKT/mTOR signaling in cancer
- Ubiquitin and proteasome pathways
- Sphingolipid Metabolism and Signaling
- Lipid Membrane Structure and Behavior

Papers in

Oncology 33
- Cancer-related Molecular Pathways 19
- Cancer Treatment and Pharmacology 8
- HER2/EGFR in Cancer Research 7
Biochemistry 6
- Lipid metabolism and biosynthesis 6

Co-authors: Paul T. Kirschmeier Robert M. Bell Linda James J E Niedel Carson R. Loomis Robert B. Stein Jin-Keon Pai Andrea Basso
Journals: Journal of Biological Chemistry (12 papers)Bioorganic & Medicinal Chemistry Letters (10 papers)Bioorganic & Medicinal Chemistry (5 papers)Proceedings of the National Academy of Sciences (2 papers)Methods in enzymology on CD-ROM/Methods in enzymology (2 papers)
Partner nations: United States United Kingdom France

In The Last Decade

W. Robert Bishop

70 papers receiving 5.7k citations

Hit Papers

align trajectories log scale

K- and N-Ras Are Geranylgeranylated in Cells Treated with Farnesyl Protein Transferase Inhibitors 1997 · 706 citations

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if any of the following hold:

it has ≥500 total citations;
it reaches ≥1.5× the top-1% citation threshold for papers in the same subfield and year (the threshold is the minimum needed to enter the top 1%, not the average within it);
it reaches the top citation threshold in at least one of its specific research topics.

1997 Journal of Biological Chemistry
1986 Journal of Biological Chemistry

Peers

Countries citing papers authored by W. Robert Bishop

Since Specialization

Citations

This map shows the geographic impact of W. Robert Bishop's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by W. Robert Bishop with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites W. Robert Bishop more than expected).

Fields of papers citing papers by W. Robert Bishop

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by W. Robert Bishop. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by W. Robert Bishop. The network helps show where W. Robert Bishop may publish in the future.

Co-authorship network

The 25 scholars most cited alongside W. Robert Bishop, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with W. Robert Bishop Line = papers co-authored together W. Robert Bishop links everyone, so they are left out of the graph.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work
1	Costello and cardio‐facio‐cutaneous syndromes: Moving toward clinical trials in RASopathies American Journal of Medical Genetics Part C Seminars in Medical Genetics ·Katherine A. Rauen, Anuradha Banerjee, W. Robert Bishop, Jennifer Lauchle, Frank McCormick, Martin McMahon, Teri Mélèse, Pamela N. Münster, Sorena Nadaf, Roger J. Packer, Judith S. Sebolt–Leopold, David Viskochil	2011	41
2	A Fully Human Insulin-Like Growth Factor-I Receptor Antibody SCH 717454 (Robatumumab) Has Antitumor Activity as a Single Agent and in Combination with Cytotoxics in Pediatric Tumor Xenografts Molecular Cancer Therapeutics ·Yaolin Wang, Philip Lipari, Xiaoying Wang, 白贵霖, Lianzhu Liang, Robert Ramos, Ming Liu, Jonathan A. Pachter, W. Robert Bishop, Yan Wang	2010	39
3	SCH529074, a Small Molecule Activator of Mutant p53, Which Binds p53 DNA Binding Domain (DBD), Restores Growth-suppressive Function to Mutant p53 and Interrupts HDM2-mediated Ubiquitination of Wild Type p53 Journal of Biological Chemistry ·Mark J. Demma, Eugene Maxwell, Robert Ramos, Lianzhu Liang, Cheng Li, David Hesk, Randall R. Rossman, Alan K. Mallams, Ronald J. Doll, Ming Liu, Cynthia Seidel‐Dugan, W. Robert Bishop, Bimalendu Dasmahapatra	2010	83
4	Combining the farnesyltransferase inhibitor lonafarnib with paclitaxel results in enhanced growth inhibitory effects on human ovarian cancer models in vitro and in vivo Gynecologic Oncology ·Kartik Gupta, J M Espadaler-Medina, Gongjie Liu, Holger Frentzel, W. Robert Bishop, Paul T. Kirschmeier, Ming Liu, Brian J. Long	2008	16
5	Enhancement of the antitumor activity of tamoxifen and anastrozole by the farnesyltransferase inhibitor lonafarnib (SCH66336) Anti-Cancer Drugs ·N. Zarrouk, J M Espadaler-Medina, Kartik Gupta, Stuart Black, Andrea Basso, Paul T. Kirschmeier, W. Robert Bishop, Ming Liu, Brian J. Long	2007	13
6	Enhanced FTase activity achieved via piperazine interaction with catalytic zinc Bioorganic & Medicinal Chemistry Letters ·F. George Njoroge, Bancha Vibulbhan, Patrick Pinto, Corey Strickland, W. Robert Bishop, Amin A. Nomeir, V. Girijavallabhan	2005	8
7	Integrative Genomics Revealed RAI3 Is a Cell Growth-promoting Gene and a Novel P53 Transcriptional Target Journal of Biological Chemistry ·Qun Wu, Wei Ding, Asra Mirza, Hagop Terzian, Iris H. Wei, W. Robert Bishop, Andrea Basso, Terri McClanahan, Lin Luo, Paul T. Kirschmeier, Eric L. Gustafson, M. Chandinipatnaik, Suxing Liu	2005	36
8	The Farnesyl Transferase Inhibitor (FTI) SCH66336 (lonafarnib) Inhibits Rheb Farnesylation and mTOR Signaling Journal of Biological Chemistry ·Andrea Basso, Asra Mirza, Gongjie Liu, Brian J. Long, W. Robert Bishop, Paul T. Kirschmeier	2005	133
9	Synthesis of 5,6-Dihydro-11H-benzo[5,6]-cyclohepta[1,2-b]pyridin-11-ylidene)-1-piperidine-N-cyanoguanidine Derivatives as Inhibitors of Ras Farnesyl Protein Transferase Bioorganic & Medicinal Chemistry Letters ·Alan Cooper, Corey L. Strickland, James Wang, Jagdish Desai, Paul T. Kirschmeier, Robert Patton, W. Robert Bishop, Patricia C Weber, V. Girijavallabhan	2002	3
10	A Phase I trial of the farnesyl transferase inhibitor SCH66336: evidence for biological and clinical activity. PubMed ·Alex A. Adjei, Charles Erlichman, J. Nathan Davis, David L. Cutler, Jeff A. Sloan, Randolph S. Marks, Lorelei J. Hanson, Phyllis A. Svingen, Pamela J. Atherton, W. Robert Bishop, Paul T. Kirschmeier, Scott H. Kaufmann	2000	201
11	Farnesyl Transferase Inhibitors Block the Farnesylation of CENP-E and CENP-F and Alter the Association of CENP-E with the Microtubules Journal of Biological Chemistry ·Hena R. Ashar, Linda James, Kimberly Gray, Donna Carr, Stuart Black, Lydia Armstrong, W. Robert Bishop, Paul T. Kirschmeier	2000	261
12	The farnesyl protein transferase inhibitor SCH66336 synergizes with taxanes in vitro and enhances their antitumor activity in vivo Cancer Chemotherapy and Pharmacology ·Bin Shi, Bohdan Yaremko, Gerald Hajian, Manuel Amorín Díaz, W. Robert Bishop, Ming Liu, Loretta L. Nielsen	2000	87
13	Combination therapy with the farnesyl protein transferase inhibitor SCH66336 and SCH58500 (p53 adenovirus) in preclinical cancer models. PubMed ·Loretta L. Nielsen, Bin Shi, Gerald Hajian, Bohdan Yaremko, Gobi Nalathambi, Eric Ferrari, Maya Gurnani, Michael G. Malkowski, Jianping Chen, W. Robert Bishop, Ming Liu	1999	26
14	Activity of SCH 66336, a tricyclic farnesyltransferase inhibitor, against human tumor colony-forming units Annals of Oncology ·Thierry Petit, Elżbieta Izbicka, R. A. Lawrence, W. Robert Bishop, Steven Weitman, Daniel D. Von Hoff	1999	21
15	Atropisomeric trihalobenzocycloheptapyridine analogues provide stereoselective FPT inhibitors with antitumor activity Bioorganic & Medicinal Chemistry ·F. George Njoroge, Bancha Vibulbhan, W. Robert Bishop, Paul T. Kirschmeier, Olga Blasco Delgado, Amin A. Nomeir, Ming Liu, Ronald J. Doll, Viyyoor Girijavallabhan, Ashit K. Ganguly	1999	3
16	Effects of SCH 59228, an orally bioavailable farnesyl protein transferase inhibitor, on the growth of oncogene-transformed fibroblasts and a human colon carcinoma xenograft in nude mice Cancer Chemotherapy and Pharmacology ·Ming Liu, Matthew Bryant, Jianping Chen, Suining Lee, Bohdan Yaremko, Lisa McAfee, Janet Dell, Gobi Nalathambi, Michael G. Malkowski, Nicholas Prioli, Randall R. Rossman, Walter A. Korfmacher, Amin A. Nomeir, Chia‐Chin Lin, Alan K. Mallams, Ronald J. Doll, Joseph J. Catino, Viyyoor Girijavallabhan, Paul T. Kirschmeier, W. Robert Bishop	1999	34
17	SCH 47112, a novel staurosporine derivative, inhibits 12-O-tetradecanoylphorbol-13-acetate-induced inflammation and epidermal hyperplasia in hairless mouse skin Archives of Dermatological Research ·Nick J. Reynolds, Stuart W. McCombie, А.М. Каплунов, W. Robert Bishop, Gary J. Fisher	1997	20
18	Endothelin-1 activates phospholipase D and thymidine incorporation in fibroblasts overexpressing protein kinase C beta 1. PubMed ·Jin-Keon Pai, KR Kelts, W. Robert Bishop	1991	34
19	Regulation of sn-1,2-diacylglycerol second-messenger formation in thrombin-stimulated human platelets. Potentiation by protein kinase C inhibitors Biochemical Journal ·W. Robert Bishop, J. T. August, Joanne Petrin, Jin-Keon Pai	1990	27
20	Enzymatic quantification of sphingosine in the picomole range in cultured cells Analytical Biochemistry ·Paul P. Van Veldhoven, W. Robert Bishop, Robert M. Bell	1989	75

About W. Robert Bishop

W. Robert Bishop is a scholar working on Oncology, Biochemistry, Molecular Biology, Toxicology and Biotechnology, having authored 71 papers that have together received 5.9k indexed citations. Recurring topics across this work include Protein Kinase Regulation and GTPase Signaling (30 papers), Cancer-related Molecular Pathways (19 papers), Cancer Treatment and Pharmacology (8 papers), PI3K/AKT/mTOR signaling in cancer (7 papers), HER2/EGFR in Cancer Research (7 papers), Biochemical and Molecular Research (6 papers), Lipid metabolism and biosynthesis (6 papers) and Melanoma and MAPK Pathways (5 papers). The work is most often cited by research in Oncology (1.9k citations), Molecular Biology (4.4k citations), Biochemistry (360 citations), Cell Biology (685 citations) and Hematology (420 citations). W. Robert Bishop has collaborated with scholars based in United States, United Kingdom and France. Frequent co-authors include Paul T. Kirschmeier, Robert M. Bell, Linda James, J E Niedel, Carson R. Loomis, Robert B. Stein, Jin-Keon Pai, Robert M. Bell, Andrea Basso and Joseph J. Catino. Their work appears in journals such as Journal of Biological Chemistry, Bioorganic & Medicinal Chemistry Letters, Bioorganic & Medicinal Chemistry, Proceedings of the National Academy of Sciences and Methods in enzymology on CD-ROM/Methods in enzymology.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact